ANDOVER, Mass., Feb. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 45^th Annual Health Care Conference in Boston on Monday, March 3, 2025, at 11:50 a.m. EST and virtually at the Oppenheimer 35^th Annual Healthcare MedTech & Services Conference on Monday, March 17, 2025, at 9:20 a.m. EST.

Event: TD Cowen 45^th Annual Health Care Conference
Date: Monday, March 3, 2025
Time: 11:50 a.m. EST

Event: Oppenheimer 35^th Annual Healthcare MedTech & Services Conference
Date: Monday, March 17, 2025
Time: 9:20 a.m. EST

A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.